Pfizer, Inc. vs Ultragenyx Pharmaceutical Inc. — Stock Comparison
Q·Score Breakdown
6.5
Neutral
Overall
5.2
Bearish
Quality
Health
Growth
Valuation
Sentiment
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
RARE
90% of 20 covering analysts have a positive rating.
⚠ currently unprofitable (-85% margin).
Analyst Consensus
HOLD
Target $29.00 (+10.2%)
27 analysts
BUY
Target $53.35 (+115.4%)
20 analysts
Fundamentals
PFE
RARE
19.4×
Trailing P/E
—
9.4×
Forward P/E
-1945.8×
12.4%
Profit Margin
-85.4%
75.8%
Gross Margin
-27.6%
8.9%
ROE
-608.5%
-1.2%
Revenue Growth
25.9%
—
Earnings Growth
—
0.39
Beta
0.25
—
Price / Book
—
$149.8B
Market Cap
$2.4B
$22 – $29
52-Week Range
$18 – $42
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →